NASDAQ$AKBA
Akebia Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Akebia's financial performance remained relatively stable with a slight increase in total revenue and a reduction in net loss compared to the same quarter last year. The company focused on managing operating expenses and advancing its regulatory and pipeline initiatives.
Akebia Therapeutics reported a slight increase in total revenue to $49.0 million, driven by a 14.9% increase in Auryxia net product revenue, offset by a decrease in license and collaboration revenue. The company's net loss was reduced to $51.9 million. Akebia is focused on managing operating expenses and pursuing regulatory approval for vadadustat.
- Total revenue increased slightly to $49.0 million compared to $48.8 million in Q3 2021.
- Auryxia net product revenue increased by 14.9% to $42.2 million compared to Q3 2021.
- Net loss decreased to $51.9 million compared to $59.5 million in Q3 2021.
- Cash and cash equivalents totaled $144.8 million as of September 30, 2022.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$49M
Revenue by segment
Akebia · $48.9M total across 2 segments · Q3 2022
- Auryxia$42.2M+14.7%86.3%
- License & other revenue$6.7M-44.2%13.7%
Forward guidance
Akebia affirmed its 2022 Auryxia net product revenue guidance of $170 - $175 million.
Tailwinds
- Affirmed 2022 Auryxia net product revenue guidance of $170 - $175M
- Based on the current review timeline, Akebia expects a decision on the MAA from EMA in the first quarter of 2023.
- Akebia continued to strengthen its balance sheet position by retiring $33 million of its $100 million debt facility with Pharmakon, inclusive of the first quarterly principal repayment.
- Akebia has since further collaborated with UTHealth to begin outlining potential next steps associated with an ARDS development program.
- By focusing on operating expenses and winding down certain projects, we’re pleased to report a reduction in spend quarter over quarter in 2022.
Headwinds
- The phosphate binder market has contracted 15%.
- A decrease from the second quarter of 2022 partially due to the drawdown of inventory at certain customers during the third quarter of 2022.
- The decrease was primarily related to a reduction in revenue from the termination of the U.S. and international collaboration agreements between Akebia and Otsuka in the second quarter of 2022.
- Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores.
- Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro